Portola Pharmaceuticals

Coagulant Therapeutics

This company develops medicines to treat acute bleeding conditions, such as postpartum haemorrhage and traumatic brain injury, for patients with urgent medical needs.

Proteon Therapeutics

This company develops pharmaceuticals to improve blood flow and vascular access for patients with kidney and vascular diseases.

Ultragenyx

This biopharmaceutical company develops and commercialises therapies for patients with serious rare and ultra-rare genetic diseases.

TargED Biopharmaceuticals

The company develops targeted biological drugs to treat thrombotic diseases such as acute ischaemic stroke and immune-mediated thrombotic thrombocytopenic purpura for healthcare providers.

Shield Therapeutics

This pharmaceutical company develops and commercialises oral iron treatments for adult and adolescent patients with iron deficiency and anaemia.

Disc Medicine

This biopharmaceutical company develops novel therapeutic candidates to treat patients suffering from serious haematologic diseases by targeting red blood cell biology and iron homeostasis.

Biohaven

This biopharmaceutical company develops therapeutics for patients with debilitating neurological, neuroinflammatory, and metabolic diseases, as well as immunological and oncology disorders.

Rocket Pharma

This company develops gene therapies for patients with rare and devastating genetic cardiovascular and haematological diseases.